Inclusion Criteria:  English-proficient men and women aged ≥18 years Free of oncologic disease by clinical examination and history Completed neurotoxic chemotherapy such as platinum agents, taxanes, vinca alkaloids, and bortezomib at least three months prior to enrollment Diagnosis of CIPN based on symptom history, loss of deep tendon reflexes, or the presence of symmetrical stocking-glove pain, numbness, or paresthesia73 Grade ≥1 sensory pain based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Self-reported moderate to severe CIPN pain, as defined by a score of 4 or greater on the BPI-SF average pain item over the past week On a stable regimen (no change in the past three months) if taking anti-neuropathy or other pain medications Willing to adhere to requirement that no new pain medication be taken throughout the first 12 weeks of the study period Willing to adhere to all study-related procedures, including randomization to one of the two possible acupuncture treatments  Exclusion Criteria:  Patients with a pacemaker or other electronically charged medical device Use of acupuncture for symptom management within the past 12 months